Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
10.3779/j.issn.1009-3419.2015.11.09
- VernacularTitle:抗PD-1/PD-L1单抗治疗肺癌临床研究进展
- Author:
HUANG ZHIYU
1
;
LI HUI
;
FAN YUN
Author Information
1. 浙江省肿瘤医院胸部肿瘤内科
- Keywords:
Checkpoint;
PD-1/PD-L1;
Monoclonal antibody;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2015;(11):706-713
- CountryChina
- Language:Chinese
-
Abstract:
Recently, the immune checkpoint inhibitors which targetprogrammed death-1 (PD-1)/PD-1 ligand (PD-L1) have made a breakthrough in the treatment of advanced non-small cell lung cancer. Researches on immune check-point inhibitors have been rapidly implemented in various types of lung cancer, such as small cell lung cancer and locally ad-vanced non-small cell lung cancer. hTese inhibitors have been applied in combination with other treatment strategies, including chemotherapy, targeting therapy and radiotherapy. However, there are still many problems to be solved, such as searching for ideal biomarkers, exploring different combination treatment models, and identifying the potential mechanisms of primary or secondary drug resistance. Along with these problems to be successfully solved, the immune checkpoint inhibitors will have broader applications in lung cancer therapy.
